{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2%2B+Cancer&page=5", "query": { "condition": "HER2+ Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1562, "total_pages": 157, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2%2B+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2%2B+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T20:45:34.221Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02732119", "title": "Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2016-06-14", "completion_date": "2020-02-25", "has_results": true, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 25, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732119" }, { "nct_id": "NCT07261631", "title": "Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-Small Cell Lung Cancer", "HR+/HER2- Ductal and Lobular Breast Cancer", "Triple Negative Breast Cancer", "Colorectal Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "68Ga-NNS309", "type": "DRUG" }, { "name": "177Lu-DFC413", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-11-24", "completion_date": "2029-05-09", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07261631" }, { "nct_id": "NCT01598077", "title": "A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma", "HER2 + Breast Cancer", "HER2 + Gastric Cancer", "Squamous Cell Carcinoma of Head and Neck", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "LJM716", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2012-07", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 4, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598077" }, { "nct_id": "NCT06435429", "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic HER2-positive Breast Cancer" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2024-08-13", "completion_date": "2030-10-18", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06435429" }, { "nct_id": "NCT00580112", "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2007-06", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 21, "location_summary": "Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westminster", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580112" }, { "nct_id": "NCT04249622", "title": "Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "HER2 Positive Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rifaximin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-09-18", "completion_date": "2022-12-27", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04249622" }, { "nct_id": "NCT00777101", "title": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 233, "start_date": "2009-02-04", "completion_date": "2018-06-03", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 44, "location_summary": "Tucson, Arizona • Murrieta, California • Orange, California + 40 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Murrieta", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777101" }, { "nct_id": "NCT01575522", "title": "Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tivantinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-03", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01575522" }, { "nct_id": "NCT04450706", "title": "Functional Precision Oncology for Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Precision Medicine", "type": "OTHER" }, { "name": "Physican Decision Making", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-02-16", "completion_date": "2024-09-05", "has_results": false, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04450706" }, { "nct_id": "NCT01042925", "title": "Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "XL147 (SAR245408)", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2010-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-10T20:45:34.221Z", "location_count": 8, "location_summary": "Los Angeles, California • Fort Meyers, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042925" } ] }